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In this work we have checked the ability of the essential oils extracted from six different medicinal plants (Eugenia caryophyllata,
Origanum vulgare, Rosmarinus officinalis, Lavandula officinalis,Melaleuca alternifolia, andThymus vulgaris) to inhibit the growth
of 18 bacterial type strains belonging to the 18 known species of the Burkholderia cepacia complex (Bcc). These bacteria are
opportunistic human pathogens that can cause severe infection in immunocompromised patients, especially those affected by cystic
fibrosis (CF), and are often resistant to multiple antibiotics.The analysis of the aromatograms produced by the six oils revealed that,
in spite of their different chemical composition, all of them were able to contrast the growth of Bcc members. However, three of
them (i.e., Eugenia caryophyllata,Origanum vulgare, andThymus vulgaris) were particularly active versus the Bcc strains, including
those exhibiting a high degree or resistance to ciprofloxacin, one of the most used antibiotics to treat Bcc infections. These three
oils are also active toward both environmental and clinical strains (isolated from CF patients), suggesting that they might be used
in the future to fight B. cepacia complex infections.
1. Introduction
Essential oils (EOs) consist of a complex blend of volatile
and fragrant substances typically synthesized by all plant
organs as secondary metabolites and extracted by water or
steam distillation, solvent extraction, expression under pre-
ssure, supercritical fluid, and subcritical water extractions [1].
EOs include two biosynthetically related groups, mainly ter-
penes and terpenoids and, secondarily, aromatic and aliphatic
constituents, all of them characterized by low molecular
weight. Biological properties of EOs terpenoids are not
well elucidated but a function of protecting plants against
predators and microbial pathogens is postulated and they
could be important in the interaction of plants with other
organisms (e.g., attraction of pollinators). The same plant
species can produce different EOs chemotypes (i.e., chemical
components). For example, Thymus vulgaris, morphologi-
cally identical species with a stable karyotype, consist of seven
different chemotypes depending on whether the dominant
component of the essential oil is thymol, carvacrol, linalool,
geraniol, sabinene hydrate, 𝛼-terpineol, or eucalyptol.
In recent years, the emergence of bacterial resistance
against multiple antibiotics has accelerated dramatically. The
quinolones/fluoroquinolones, azole, and polyene classes of
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antimicrobials often are the last resort to treat infections;
hence the chances of acquiring resistance against these
antimicrobials are higher [2]. EOs and other plant extracts
possess antibacterial, antifungal, and antiviral properties
and have been screened worldwide as potential sources of
novel antimicrobial compounds [3]. Thus EOs and their
constituents can hopefully be considered in the future for
more clinical evaluations and possible applications and as
adjuvants to current medications [4]. The antimicrobial
properties of EOs have been reported in several studies. High
antimicrobial activity of Thymus and Origanum species has
been attributed to their phenolic components such as thymol
and carvacrol and those of Eugenia caryophyllus, Syzygium
aromaticum, and Ocimum basilicum to eugenol [1]. In fact
thyme and oregano EOs can inhibit some pathogenic bac-
terial strains such as Escherichia coli, Salmonella enteritidis,
Salmonella cholerasuis, and Salmonella typhimurium, with
the inhibition directly correlated to carvacrol and thymol
[5]. The mechanisms by which essential oils can inhibit
microorganisms involve different modes of action and in
part may be due to their hydrophobicity. As a result, they
get partitioned into the lipid bilayer of the cell membrane,
rendering it more permeable, leading to leakage of vital cell
contents [6]. There are fewer reports on the mechanisms
of action of EOs combination or their purified components
on microorganisms. They include the sequential inhibition
of a common biochemical pathway, inhibition of protective
enzymes, and use of cell wall active agents to enhance the
uptake of other antimicrobials.The capacity of hydrocarbons
to interact with cell membrane facilitates the penetration
of carvacrol into the cell. In many cases the activity results
from the complex interaction between the different classes
of compounds such as phenols, aldehydes, ketones, alcohols,
esters, ethers, or hydrocarbons found in EOs [1]. It is likely
that it will be more difficult for bacteria to develop resistance
to the multicomponent EOs than to common antibiotics that
are often composed of only a single molecular entity [3].
For example the multicomponent nature of tea tree oil could
reduce the potential for resistance to occur spontaneously,
since multiple simultaneous mutations may be required to
overcome all of the antimicrobial actions of each of the
components. This means that numerous targets would have
to adapt to overcome the effects of the oil [7].
Clinical studies with EOs are scarce. Topical use is the
most promising strategy at the moment, for both skin and
mucous membranes. Some hope exists for inhalation uses,
but clinical evaluation is needed. There is little information
regarding safety in relation to oral administration of EOs,
so an increase in the knowledge about pharmacokinetics,
pharmacodynamics, and the potential toxicity of EOs admin-
istered by this route is required [3].
Particularly interesting from this viewpoint is the pos-
sibility to treat infections of cystic fibrosis (CF) patients.
One of the most important opportunistic CF pathogens
is represented by bacteria belonging to the Burkholderia
cepacia complex (Bcc) belonging to the very heterogeneous
genus Burkholderia, which currently comprises more than
seventy species, isolated from wide range of niches. Many
members of the genus can cause infection in plants, animals,
and humans, and most studies have thus focused on these
pathogenic species due to their clinical importance [8].
However, recently, an increasing number of Burkholderia
species associated with plants or with the environment and
able to fix nitrogen, to nodulate legume or to promote plant
growth, were described [8]. Among the pathogenic species,
the Bcc bacteria, a group of genetically distinct but phe-
notypically similar bacteria that up to now comprises 18
closely related bacterial species [9, 10], have become known
as opportunistic pathogens in humans. Although they are
not considered important pathogens for the normal human
population, some of them are considered serious threats
for specific patient groups such as CF patients [11]. CF is
the most fatal genetic disease of Caucasians [9], and the
main cause of morbidity and mortality in patients is chronic
lung infection involving different species of bacteria (mainly
Pseudomonas aeruginosa), fungi, and viruses [12]. Regarding
Bcc species, the prevalence (2009 and 2010) of chronic
infection is reported to vary between 0 and 12% of the CF
population attending various CF centres [13]. Although it is
not high compared to other CF pathogens, Bcc infections
correlate with poorer prognosis, longer hospital stays, and an
increased risk of death [14].
One of the reasons for the high rate of mortality in
infections caused by Bcc species is their high resistance to
antibiotics: they are intrinsically resistant to many antibiotics
and can develop in vivo resistance to essentially all classes of
antimicrobial drugs [14, 15]. This high antibiotics resistance
is the result of mechanisms specific for certain classes of
antibiotics and of an intrinsic resistance, characteristic of all
Gram-negative bacteria, due to the cooperation between the
outer membrane barrier and the expression of efflux systems
[14, 16]. Between multidrug efflux systems, the intrinsic drug
resistance of Gram-negative bacteria is mainly attributable
to RND (resistance-nodulation-cell division protein family)
type drug exporters [17]. The presence and distribution
of these kinds of proteins in some available Burkholderia
genomes are known [18, 19], and some of these systems have
also been experimentally characterized [20–23].
New antimicrobial agents are always needed to counteract
the Bcc resistant mutants that continue to be selected by cur-
rent therapeutic regimens. Bacterial resistance often results
in treatment failure that causes severe aftermath especially
in critically ill patients [24]. Inappropriate or unnecessary
antibiotic prescriptions, the excessive use of antibiotics in
the agricultural and livestock industries, and the lack of
patient adherence to full antibiotic regimens, all of which
select resistant bacteria, appear to be the key contribu-
tors to the emergence of antibiotic resistance. Resistant
bacteria may also spread and become broader infection-
control problems, not only within healthcare institutions
but within communities as well. For this reason there is a
pressing need to develop new antibacterial therapies not only
against Bcc bacteria but also against other different human
pathogens [25]. In this context one of the most important
approaches is represented by the search of new natural drugs
from “unusual” sources; particularly interesting might be the
essential oils since they are multi-component and, in princi-
ple, the probability of bacteria to develop resistance to this
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Table 1: List of bacterial strains used in this work and their sensitivity to the essential oils tested in this work.
Burkholderia cepacia complex strains
Strain Origin Species Sensitivity to
Eugenia
caryophyllata
Origanum
vulgare
Rosmarinus
officinalis
Lavandula
hybrida
Melaleuca
alternifolia
Thymus
vulgaris
Ciprofloxacin
LMG 13010 CF B. multivorans ES ES S S S ES VS
J2315 CF B. cenocepacia ES ES S S S ES S
LMG 14294 CF B. stabilis ES ES S S S ES NS
LMG 24064 CF B. latens ES ES ES S S ES ES
LMG 24065 CF B. diffusa ES ES VS S S ES VS
LMG 18943 CF B. dolosa ES ES VS S VS ES NS
LMG 24067 CF B. seminalis ES ES S S S ES VS
LMG 24068 CF B. metallica ES ES S S S ES ES
LMG 26883 CF B. pseudomultivorans ES ES VS S S ES VS
LMG 23361 AI B. contaminas ES ES VS S S ES ES
LMG 1222 Env B. cepacia VS ES S S S ES VS
LMG 10929 Env B. vietnamiensis ES ES ES S VS ES ES
LMG 19182 Env B. ambifaria ES ES NS S S ES ES
LMG 20980 Env B. anthina ES ES VS S ES ES ES
LMG 14191 Env B. pyrrocinia ES ES VS S ES ES ES
LMG 22485 Env B. lata ES ES S S S ES ES
LMG 24066 Env B. arboris ES ES VS S S ES ES
LMG 20358 Env B. ubonensis ES ES ES S VS ES ES
CF: strain isolated from cystic fibrosis patient; Env: environmental strain; AI: animal infection; NS, S, VS, and ES: not sensitive, sensitive, very sensitive, and
extremely sensitive, respectively (according to Ponce et al., 2003) [26].
mixture of substances might be much lesser than to a single
molecule.
Therefore, the aim of this work was to explore the antimi-
crobial activity of six different essential oils versus a panel
of Bcc bacteria, some of which exhibiting multiresistance
to different drugs and with either clinical or environmental
source, in order to check the possibility of using essential oils
to fight Bcc infections in CF patients.
2. Materials and Methods
2.1. Bacterial Strains and Growth Conditions. The bacterial
strains used in this work are listed inTable 1.Theywere grown
either on Tryptone Soya Agar (TSA, Oxoid S.p.A., Strada
Rivoltana, 20090 Rodano, MI, Italy) medium at 37∘C for two
days or in liquid Tryptone Soya Broth (TSB, Oxoid S.p.A.,
Strada Rivoltana, 20090 Rodano, MI, Italy) medium at 37∘C
with shaking.
2.2. Aromatograms
2.2.1. Preparation of Microbial Suspensions and Media. Each
bacterial strain was grown at 37∘C in liquid medium (TSB)
with shaking; the growth was checked at regular time inter-
vals (as spectrophotometric reading at OD
600
) until the end
of the growth exponential phase was reached. Serial dilutions
1 : 10 to 10−5 of each bacterial suspension were plated on TSA
Petri dishes in order to count the microorganisms and verify
that the number of bacteria in the samples was appropriate to
the performance of the tests.
TSA, used to perform the agar diffusion assays, was enri-
ched with a suitable volume of Dimethylsulphoxide (DMSO,
Carlo Erba Reagenti S.p.a., Strada Rivoltana km 6/7, 20090
Rodano, MI, Italy), sterilized by filtration through filters
with a pore diameter of 0.22𝜇m (Sartorius Italy Srl, Viale
A. Casati 4, 20835 Muggio`, MB, Italy), thus obtaining 0.5%
(v/v) solutions identified by the abbreviations of DTSA. The
addition of DMSO, an aprotic organic solvent belonging to
the category of sulfoxides, had the purpose of facilitating
the solubilisation of essential oils in the aqueous medium
represented by the culture media.
2.2.2. Preparation of Dilutions of Essential Oils. The essential
oils used in this study (Eugenia caryophyllata, Origanum
vulgare,Rosmarinus officinalis, Lavandula hybrida,Melaleuca
alternifolia andThymus vulgaris) were all extracted by steam
distillation method, and purchased from the same retailer
(Prodotti Phitocosmetici Dott. Vannucci di VannucciDaniela
e C. Sas, Via la Cartaia Vecchia 3, 59021 Vaiano (PO), Italy).
All EOs and EOs dilutions were stored at 4∘C before use.
2.2.3. Agar Disk Diffusion Assay. Burkholderia cell suspen-
sions were streaked on DTSA Petri dishes. Sterile filter paper
disks (Oxoid SpA. Strada Rivoltana, 20090 Rodano, MI,
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Italy) of 6mm diameter were soaked with 10 𝜇L of each not
diluted EO, and placed on the surface of the dishes. In
addition, positive and negative controls were applied to the
surface of agar plates; they were, respectively, the antibiotic
ciprofloxacin (3 𝜇g/10 𝜇L) (Oxoid S.p.A. Strada Rivoltana,
20090 Rodano, MI, Italy) and a solution of DMSO 0.5% in
sterile deionised water. The plates were incubated at 37 ± 1∘C
for 48 h aerobically. After incubation, the diameter of the
inhibition zones was measured in millimeters, including the
diameter of disk. The sensitivity to the EOs was classified by
the diameter of the inhibition zones as follows: not sensitive
for total diameter smaller than 8mm, Sensitive for total
diameter 9–14mm, very sensitive for total diameter 15–19mm,
and extremely sensitive for total diameter larger than 20mm
[26]. Each assay was performed in triplicate on three separate
experimental runs.
2.3. Determination of Essential Oil Composition. Gas cro-
matographic (GC) analyses were accomplished with an HP-
5890 series II instrument equipped with a HP-5 capillary
column (30 𝜇m × 0.25mm, 0.25𝜇m film thickness), working
with the following temperature program: 60∘C for 10min,
ramp of 5∘C/min to 220∘C; injector and detector tempera-
tures, 250∘C; carrier gas, nitrogen (2mL/min); detector, dual
flame ionization detection (FID); split ratio, 1 : 30; injection,
0.5 𝜇L. The identification of the components was performed,
for both columns, by comparison of their retention times
with those of pure authentic samples and by means of their
linear retention indices (LRI) relative to the series of 𝑛-
hydrocarbons. Gas chromatography-electron impact mass
spectrometry (GC-EIMS) analyses were performed with
a Varian CP 3800 gas chromatograph (Varian, Inc. Palo
Alto, CA) equipped with a DB-5 capillary column (Agi-
lent Technologies Hewlett-Packard, Waldbronn, Germany;
30m × 0.25mm, coating thickness 0.25mm) and a Varian
Saturn 2000 ion trap mass detector. Analytical conditions
were as follows: injector and transfer line temperature at
250 and 240∘C, respectively, oven temperature being pro-
grammed from 60 to 240∘C at 3∘C/min, carrier gas, helium at
1mL/min, splitless injector. Identification of the constituents
was based on comparison of the retention times with those
of the authentic samples, comparing their LRI relative to
the series of n-hydrocarbons and on computer matching
against commercial and homemade librarymass spectra built
from pure substances and components of known samples
and MS literature data [27–32]. Moreover, the molecular
weights of all the identified substances were confirmed by
gas chromatography-chemical ionization mass spectrom-
etry (GC-CIMS), using methanol as chemical ionization
gas.
2.4. Statistical Analyses. Inhibition zones in Bcc strains from
the different EOs were analyzed by using principal compo-
nent analysis as implemented in PAST software [33]. Kruskal-
Wallis test with Bonferroni error protection was applied for
comparing the overall inhibition zones from the different
EOs by using the Analyse-it software (Analyse-it Software,
Ltd.).
3. Results and Discussion
3.1. Composition of Essential Oils. Essential oils are very
complex natural mixtures, which can contain about 20–60
components at quite different concentrations.They are chara-
cterized by two or threemajor components at fairly high con-
centrations (20–70%) compared to other components pre-
sent in trace amounts. Terpenoids (mainly monoterpenoids
and sesquiterpenoids) generally represent the principal con-
stituents but some essential oils are characterised by the
presence of aromatic (phenylpropanoids) and aliphatic con-
stituents, all characterized by low molecular weight.
The tested essential oils were commercial samples and
analysed by GC using as detector a dual FID and electron
impact mass spectrometry. Constituents were identified by
comparison of their retention times of both columns with
those of pure authentic samples and by means of their linear
retention indices (LRI) relative to the series of 𝑛-hydro-
carbons and MS data from homemade library mass spectra
and literature.
Almost 100% of the volatiles of oregano essential oil
were identified, being 77.2% of oxygenated monoterpenes,
principally represented by carvacrol representing 71.8% of
the total essential oil; 19.2% of constituents were represented
by monoterpene hydrocarbons, principally 𝑝-cymene; 2.9%
were sesquiterpenes hydrocarbons, and 0.6% were oxy-
genated sesquiterpenes.
Also in the case of rosemary essential oil the identified
volatiles were 99.9% andmajor constituents were represented
by oxygenatedmonoterpenes (64.6%) being themain volatile
1,8-cineole (43.9%). Monoterpene hydrocarbons were 25.9%,
principally 𝛼-pinene. Sesquiterpene hydrocarbons were 9.1%
and oxygenated sesquiterpenes were only 0.3%.
Total identified constituents of thyme oil were 99.5%.
These volatiles were characterized by 53.7% of monoter-
pene hydrocarbons being 47.9% p-cymene and oxygenated
monoterpenes 45.6%, principally thymol (43.1%). Only 0.2%
of the volatiles were sesquiterpenes hydrocarbons.
About 98% of constituents of clove oil were identified and
the main metabolite was eugenol (85%), a typical phenyl-
propanoid, while 11.2% of the constituents were recognised as
sesquiterpene hydrocarbons being 𝛽-caryophyllene the main
molecule (9%).
Approximately all (99.1%) of the constituents of M.
alternifoliawere identified; principal compoundswere oxyge-
nated monoterpenes being 4-terpineol the principal one
(39.9%). The rest of the oil was mainly represented by mono-
terpene hydrocarbons (41.4%) being 𝛾-terpinene (14.4%) and
𝛼-terpinene (8.8%) the principal molecules.
3.2. Antimicrobial Activity of the Essential Oils against
Burkholderia cepacia Complex (Bcc) Strains. The antimicro-
bial activity of the six different EOs (E. caryophyllata (Ec),
O. vulgare (Ov), R. officinalis (Ro), L. hybrida (Lh), M. alte-
rnifolia (Ma), and T. vulgaris (Tv)) was checked versusthe 18
Bcc type strains listed in Table 1 and representative of the
18 known Bcc species; this panel comprises strains of either
clinical or environmental origin.
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Figure 1: Inhibitory power of essential oils. Results for the agar diffusion assay performed on the 18 Bcc type strains are presented. Each
bar of the histogram represents the mean of the inhibitory zone obtained for each of the EOs analyzed. In the graphics are reported the
standard deviations for every arithmetic average obtained: (1)Thymus vulgaris, (2) Rosmarinus officinalis, (3) Lavandula hybrida, (4) Eugenia
caryophyllata, (5)Melaleuca alternifolia, (6) Origanum vulgare, and (7) Ciprofloxacin.
Data obtained are reported in Figure 1 and showed the
following.
(i) All the 18 bacterial strains, from both clinical and
environmental origin, exhibited, although at a differ-
ent extent, sensitivity to each of the six EOs tested.
(ii) According to Ponce et al. [26], three essential oils, that
is, Ec, Tv, and Ov, exhibited a very high inhibitory
power versus all the Bcc strains tested. Indeed, all of
them were extremely sensitive to these three EOs.
(iii) Quite interestingly, these three EOs gave an inhibitory
halomuch larger than that produced by ciprofloxacin,
suggesting that they are more active than this antibi-
otic.
(iv) The other three EOs (Ro, Lh, and Ma) exhibited
a degree of inhibition of Bcc growth lower than
that exhibited by the three EOs mentioned above;
however, the inhibitory halos they produced were
similar and in many cases larger than those exhibited
by ciprofloxacin.
(v) Apparently, clinical and environmental strains did not
exhibit a different sensitivity to a given EO (or to
a set of EOs), but they were differently sensitive to
ciprofloxacin (Table 1). Two of them, that is, LMG
14294 (B. stabilis) and LMG 18943 (B. dolosa), were
resistant to the antibiotic and B. cenocepacia J2315,
representing the model system for the study of Bcc
infection in CF patients, exhibited a low sensitivity
to ciprofloxacin. These three strains have a clinical
origin. In spite of this, the same three strains were
extremely sensitive to the three most active EOs.
(vi) Environmental Bcc strains were much more sensitive
to ciprofloxacin than their clinical counterparts.
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Figure 2: Differences in the patterns of inhibition of essential oils. Upper panel: principal component analysis biplot of inhibitory patterns
18 Bcc strains (centroids) treated with different EOs and ciprofloxacin (C+). The percentage of variance explained by the first two principal
components is reported. Lower panel: 𝑃 values of pairwise comparisons (Kruskal-Wallis test and Bonferroni error protection) between EOs
and C+. n.s.: not significant; ∗𝑃 < 0.01; ∗∗𝑃 < 0.001; ∗∗∗𝑃 < 0.0001.
The differential sensitivity to EOs and ciprofloxacin was
confirmed by a principal component analysis (Figure 2). As
shown in the biplot the vectors accounting for EOs are
differentially oriented than those of ciprofloxacin (C+).
Moreover, the vectors for Ov and Tv greatly contributed in
the differential pattern of sensitivity, thus confirming that
the most active essential oils were T. vulgaris and O. vulgare.
Finally a pairwise comparison (Kruskal-Wallis test) of the
patterns of inhibition of EOs and ciprofloxacin (Figure 2)
showed that large differences between inhibitory halos of
different EOs and ciprofloxacin are present, highlighting
the observed (Table 1, Figure 1) differences in the inhibitory
power of the six EOs.
4. Conclusions
In this work we have performed a preliminary analysis of the
ability of six different essential oils to inhibit the growth of
strains belonging to the B. cepacia complex, whose members
are dangerous for CF patients; indeed they can cause severe
infections in immune-compromised patients, such as those
affected by cystic fibrosis.This idea relies on previous findings
demonstrating that essential oils are able to inhibit the growth
of some human pathogens, such as E. coli, S. enteritidis, S.
choleraesuis, and S. typhimurium [5]. However, to the best
of our knowledge, nothing are known on the ability of these
mixtures of chemical compounds to inhibit the growth of Bcc
members.
For this reason we selected six different essential oils
(E. caryophyllata, O. vulgare, R. officinalis, L. officinalis, M.
alternifolia, and T. vulgaris) that were tested versus a panel
embedding the type strains of the known 18 Bcc species.
The composition of the six EOs was quite different but,
in spite of this, all of them exhibited an inhibitory activity
versus all the 18 Bcc strains, suggesting that one compound or
(more likely) more than one compound (see below) present
in each essential oil might interfere with the Bcc cell growth.
However, the six essential oils showed a different inhibitory
activity and according to Ponce et al. [26] they might be split
into two different clusters; the first one includesT. vulgaris, O.
vulgare andE. caryophyllata, whereas the other one embedsR.
officinalis, M. alternifolia and L. officinalis (Table 2). Indeed,
Bcc strains were extremely sensitive to the EOs belonging to
the first group and just sensitive to the other three.
However, all of them are able to inhibit the growth of
Bcc strains; particularly interesting and intriguing is the
finding that the inhibitory halos produced by most of EOs
are (muchmore) larger than those produced by ciprofloxacin,
one of the antibiotics used in CF infections therapy. We
are completely aware that the sensitivity to a given drug
or to a complex mixture of antimicrobial compounds may
strongly vary also between strains belonging to the same
bacterial species. However, in our opinion, the preliminary
data reported in this work are particularly encouraging, since
they demonstrate that the use of essential oilsmight represent
an alternative way to fight Bcc growth. It is also quite
interesting that, in spite of the high number of experiments
performed in this work, no Bcc mutant resistant to any of
the essential oils tested was isolated (data not shown). This
represents a very important finding, which strongly suggests
Evidence-Based Complementary and Alternative Medicine 7
Table 2: Composition (%) and principal classes (%) of the six essential oils used in this work.
Constituents LRI
Essential oil
Lavandula
hybrida
Eugenia
caryophyllata
Melaleuca
alternifolia
Origanum
vulgare
Rosmarinus
officinalis
Thymus
vulgaris
Tricyclene 928 0.2 tr
𝛼-Thujene 933 0.6 tr
𝛼-Pinene 941 0.4 0.2 3.8 1.7 11.5 4.3
Camphene 955 0.3 tr 0.4 4.1 0.1
Thuja-2.4(10)-diene 959 tr
Sabinene 977 0.1 tr 0.6
𝛽-Pinene 982 0.6 0.1 2.1 0.4 3.8 1.2
Myrcene 993 0.5 0.6 1.3 1.3
𝛼-Phellandrene 1006 0.4 tr 0.2
1-Hexyl acetate 1010 0.1
𝛿-3-Carene 1013 tr tr tr
1.4-Cineole 1018 0.1
𝛼-Terpinene 1020 tr 8.8 0.8 0.4
𝑝-Cymene 1027 0.3 tr 3.7 11.6 1.9 47.9
Limonene 1032 0.7 0.1 2.0 1.1 1.8 0.2
1.8-Cineole 1034 6.9 tr 2.9 0.6 43.9 0.2
(𝑍)-𝛽-Ocimene 1042 0.3
𝛾-Terpinene 1063 tr 14.4 1.7 0.4
cis-Sabinene hydrate 1070 0.1 tr tr
cis-Linalool oxide (furanoid) 1077 0.3
Terpinolene 1090 4.4 0.2 0.3
trans-Linalool oxide (furanoid) 1090 0.2
1-Pentyl butyrate 1094 tr
trans-Sabinene hydrate 1099 0.3
Linalool 1101 27.1 1.8 0.9 1.2
1-Octenyl acetate 1112 0.4
exo-Fenchol 1118 tr tr tr
cis-p-Menth-2-en-1-ol 1123 0.4
Terpinen-1-ol 1135 0.2
trans-Pinocarveol 1141 tr
trans-p-Menth-2-en-1-ol 1142 0.4
Camphor 1145 8.4 tr 11.3
1-Hexyl isobutyrate 1152 0.2
Isoborneol 1158 0.2
trans-Pinocamphone 1162 tr
Pinocarvone 1164 tr
Borneol 1168 3.2 0.4 4.2
Lavandulol 1171 0.6
cis-Pinocamphone 1175 tr
4-Terpineol 1178 3.9 tr 39.9 0.2 0.8
𝑝-Cymen-8-ol 1185 tr
𝛼-Terpineol 1190 1.7 4.2 0.4 2.6 0.6
1-Hexyl butyrate 1193 0.6
cis-Piperitol 1195 tr
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Table 2: Continued.
Constituents LRI
Essential oil
Lavandula
hybrida
Eugenia
caryophyllata
Melaleuca
alternifolia
Origanum
vulgare
Rosmarinus
officinalis
Thymus
vulgaris
Verbenone 1206 0.2
trans-Piperitol 1207 0.2
Nerol 1230 0.2
1-Hexyl 2-methylbutyrate 1235 0.1
1-Hexyl 3-methylbutyrate 1244 0.3
Chavicol 1252 tr
Linalyl acetate 1259 30.4
trans-Ascaridolglycol 1268 0.2
Isobornyl acetate 1287 0.2 0.7
Lavandulyl acetate 1291 3.3
Thymol 1292 1.6 43.1
Carvacrol 1301 71.8 0.4
1-Hexyl tiglate 1333 0.2
𝛼-Cubebene 1352 tr tr
Eugenol 1358 85.0
Neryl acetate 1365 0.4
𝛼-Ylangene 1373 0.2
𝛼-Copaene 1377 0.2 tr tr 0.6
Geranyl acetate 1383 1.0
𝛼-Gurjunene 1410 0.5
𝛽-Caryophyllene 1419 2.2 9.0 0.5 2.7 5.1 0.2
Lavandulyl isobutyrate 1424 0.1
trans-𝛼-Bergamotene 1437 0.2 tr
𝛼-Guaiene 1440 1.4 0.2
(Z)-𝛽-Farnesene 1444 0.2
𝛼-Humulene 1455 tr 1.4 0.1 0.2 0.5 tr
(E)-𝛽-Farnesene 1459 1.1
Alloaromadendrene 1461 0.6
𝛾-Muurolene 1478 0.6
Germacrene D 1482 0.3
Valencene 1493 0.3
Viridiflorene 1494 1.3 0.2
Bicyclogermacrene 1496 0.7
𝛼-Muurolene 1499 0.2 0.2
𝛽-Bisabolene 1509 0.2 0.2
Lavandulyl 2-methylbutyrate 1513 0.4
trans-𝛾-Cadinene 1514 0.5 0.4
𝛿-Cadinene 1524 0.6 1.8 0.9
trans-Cadina-1(2).4-diene 1534 0.2
Spathulenol 1577 0.2
Caryophyllene oxide 1582 0.6 0.5 0.6 0.3 tr
Globulol 1584 0.5
Guaiol 1597 0.2
1-epi-Cubenol 1629 0.3
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Table 2: Continued.
Constituents LRI
Essential oil
Lavandula
hybrida
Eugenia
caryophyllata
Melaleuca
alternifolia
Origanum
vulgare
Rosmarinus
officinalis
Thymus
vulgaris
T-Cadinol 1640 0.2
Cubenol 1643 0.2
𝛼-Bisabolol 1684 0.4
Monoterpene hydrocarbons 3.2 0.4 41.4 19.2 25.9 53.7
Oxygenated monoterpenes 88.2 0.0 48.7 77.2 64.6 45.6
Sesquiterpene hydrocarbons 4.7 11.2 7.6 2.9 9.1 0.2
Oxygenated sesquiterpenes 1.2 0.5 1.4 0.6 0.3 tr
Phenylpropanoids — 85.0 — — — —
Other derivatives 1.9 — — tr — —
Total identified 99.2 97.1 99.1 99.9 99.9 99.5
LRI: linear retention indices relative to the series of 𝑛-hydrocarbons; tr: traces.
that the ability of essential oils to inhibit the growth of Bcc
cells might be very likely due to the simultaneous presence
in the oil of different molecules (whose mechanism of action
is still unknown) that might work in a synergistic fashion to
antagonize the Bcc growth. In addition to this, in our opinion,
these combinations of compounds should not act on a single
target, but on different molecular targets within the Bcc cell.
If this is so, the simultaneous block of the activity of different
molecular targets should strongly decrease the probability of
the appearance of a mutant able to resist the essential oils. If
this scenario is correct, these data might pave the way to the
use of essential oils to fight Bcc infection in CF patients.
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